protein

Hydroxysteroid Dehydrogenase, 11-beta Type II, Human (11b-HSD2) (Control Peptide)

MBS653968

0.05 mg

240 USD

Peptide

Hydroxysteroid Dehydrogenase, 11-beta Type II, Human (11b-HSD2) (Control Peptide)

Hydroxysteroid Dehydrogenase, 11-beta Type II

Human synthetic peptide

A 19aa synthetic peptide, mapping near the C-terminus of human 11beta-HSD2

Highly purified

Supplied as a liquid in PBS, pH 7.5.

1mg/ml

May be stored at 4 degree C for short-term only. For long-term storage, store at -20 degree C. Aliquots are stable for at least 6 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Elisa (EIA), Antibody Blocking

Suitable for use in ELISA and Antibody Blocking. Not suitable for use in Western Blot. Other applications not tested. ELISA: 50-100ng control peptide/well. Antibody Blocking: 5-10ug per 1ug MBS618093 (affinity purified) or per 1ul MBS614847 (antiserum). Optimal dilutions to be determined by the researcher.

Species sequence homology: No significant sequence homology is seen with 11b-HSD1 or other proteins. No Significant homology with rat or mouse 11beta-HSD2

Principle: It is not uncommon to see more than 1 band in Western Blot when probed with a given antibody or see more diffuse staining in immuno-Iocalization studies. The question arises which one of this band(s)/staining is specific. The antibody specificity is generally studied by competing with excess of antigen (peptide or protein) or immuno-neutralization with the antigens. In principle, a small volume of antibody (e.g. 1-5ul) is first reacted with excess peptide (5-50 fold over the antibody e.g., 1 ug antibody reacted with 5-50ug peptide; exact amounts determined by titration) to neutralize it. The neutralized antibody can no longer subsequently bind to another antigen (a band of interest) or staining pattern. So the band(s)/staining that is competed by the antigen/peptide is supposedly specific. If more than one band disappears by peptide/antigen competition then those bands have the antigenic determinants and could be considered either fragments of the large antigen or multimer.

Molecular Biology; MB-Enzymes, Dehydrogenase

Control Peptide for MBS614847 (antiserum) and MBS618093 (affinity purified) antibodies. 11-b-hydroxysteroid dehydrogenase (11b-HSD) is a microsomal short chain dehydrogenase/reductase (SDR) which catalyzes the inter-conversion of biologically active glucocorticoid (cortisol in human and corticosterone in rats and mice) and inactive glucocorticoid (cortisone and 11-dehydrocorticosterone). Two tissue specific isoforms (11b-HSD1 and 11b-HSD2) of 11b-HSD with two different functions regarding glucocorticoid availability, have been identified. The decreased 11b-hydroxy oxidation of cortisol results in Apparent Mineralocorticoid Excess (AME) disorder which is manifested by hypertension, hypokalemia, low plasma renin activity, and responsiveness to spironolactone. AME is principally a disorder of juveniles and children with this condition oxidize cortisol to cortisone poorly but carry out the reverse process unimpaired. AME arises from mutations in the 11b-HSD2 gene. The glucocorticoids can also be produced locally by 11b-HSD1 and increased visceral accumulation of glucocorticoids results in visceral obesity, insulin resistant diabetes, hyperlipidemia and hyperphagia. 11bHSD-2 (rat 400-aa, mouse 396-aa, human 405-aa) is a ~41kD glycosylated membrane-protein present in the endoplasmic reticulum (ER). The N-terminal and C-terminal (catalytic domain) of 11b-HSD2 are in the lumen and cytoplasm of ER, respectively. 11b-HSD2 irreversibly catalyzes the dehydrogenation of active 11b-hydroxycorticoids before they occupy mineralocorticoid receptors (MR) and thus confers aldosterone selectivity for inherently nonselective MR.

0.05 mg

240 USD